The KOR represents an excellent therapeutic target for developing analgesics with mitigated adverse effects, because its activation does neither contribute to the development of MOR-based respiratory depression nor addiction (Darcq and Kieffer, 2018). This evidence concerns the gene OPRK1 and Respiratory insufficiency due to muscle weakness.